DOACs can prevent serious thrombotic events like stroke in residents with nonvalvular atrial fibrillation (NVAF) and have a lower risk of major bleeding events than warfarin.
Persons receiving standard-dosing of DOACs experienced 1.4 more major bleeds per 100 person-years than those on reduce-dosing, with highest relative bleeding rates among those aged ≥80 years or who were not obese.
Over the 1-year follow-up period, the overall rate of major bleeds in this population was 8.6 per 100 person-years (PY) and 5.7 per 100 PY for thrombotic events.
The findings were reported in the article, Benefits and Harms of Standard versus Reduced-Dose Direct Oral Anticoagulant Therapy for Multimorbid Older Adults with Atrial Fibrillation, published in the Journal of the American Heart Association.
More information:
Kaleen N. Hayes et al, Benefits and Harms of Standard Versus Reduced‐Dose Direct Oral Anticoagulant Therapy for Older Adults With Multiple Morbidities and Atrial Fibrillation, Journal of the American Heart Association (2023). DOI: 10.1161/JAHA.122.029865
Provided by
Hebrew SeniorLife Hinda and Arthur Marcus Institute for Aging Research
Citation:
Study supports use of reduced-dose of direct oral anticoagulants for many older adults with two or more conditions (2023, November 7)
retrieved 7 November 2023
from https://medicalxpress.com/news/2023-11-reduced-dose-oral-anticoagulants-older-adults.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
